Compare

Kailera Therapeutics/$KLRA

1D1W1M3M6MYTD1Y5YMAX

About Kailera Therapeutics

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Ticker
$KLRA
Sector
Health
Primary listing
NASDAQ
Employees
-
Headquarters
Waltham, United States
Website
www.kailera.com

KLRA Metrics

BasicAdvanced
$1.7B
-
-$2.25
-
-

What the Analysts think about KLRA

Analyst ratings (Buy, Hold, Sell) for Kailera Therapeutics stock.
Analyst projections of the future price of Kailera Therapeutics stock.

Bulls say / Bears say

KAI-7535 met the primary endpoint in a Phase 3 Chinese obesity trial, producing up to 10.9% mean weight loss at Week 44 and 11.1% at Week 50, versus about 2.5% to 2.6% with placebo. The same asset also lowered HbA1c in a Phase 3 diabetes trial, giving Kailera evidence in two indications. (Reuters, Kailera Therapeutics)
The pipeline has several shots on goal: ribupatide injection is in a three-trial global Phase 3 programme, while its oral version showed up to 12.1% mean weight loss at Week 26 with no observed plateau and now has an active US FDA IND. This breadth could reduce reliance on the poorly tolerated KAI-7535 asset. (SEC filing, Reuters)
Kailera held $1.17 billion in cash, cash equivalents and marketable securities at 30 June 2026, which management expects to fund operations into mid-2028. That should allow it to reach several planned 2027 milestones without an immediate need to rely on volatile capital markets. (SEC filing)
KAI-7535 met its Phase 3 efficacy goal, but tolerability is a major commercial risk: nausea affected about 70% of treated patients and vomiting more than 65%, versus 16.2% and 4.5% with placebo. Shares fell 10% after the readout, showing the market’s concern. (Reuters)
Kailera’s most important ribupatide injection programme is still in Phase 3, with global data expected only in 2028. That leaves a long period in which trial results, regulatory feedback or execution could disappoint before the main valuation catalyst arrives. (SEC filing)
Kailera is pre-revenue and reported a $190.2 million net loss for the first half of 2026. It expects further losses and warns that failure to raise additional capital could delay, reduce or stop development programmes, creating dilution and funding risk despite its current cash runway. (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.

KLRA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

KLRA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing KLRA

Funds
Fund name
Fund size
$KLRA weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.02%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.02%
SPDR MSCI All Country World IM€SPYI
$7.7B0.00%
iShares MSCI World Small Cap£WLDS
$9B0.00%
iShares MSCI World Small Cap€IUSN
$9B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.